GlassScriptPhysician profile
Boris Valdman
NPI 1275582835
$1,277.99
in general payments reported to CMS, 2019-2025
24 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.51 · 2021: $33.16 · 2022: $75.85 · 2023: $118 · 2024: $392 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $210.71 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $177.73 | 2023-2025 | |
| Lilly USA, LLC | $125.02 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $109.29 | 2022-2024 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.73 | 2024-2025 | Jardiance |
| Abbott Laboratories | $68.92 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $61.64 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.95 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.34 | 2024 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $39.33 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $31.56 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $29.13 | 2025 | Evenity |
| Medtronic, INC. | $28.62 | 2025 | Inceptiv |
| Janssen Pharmaceuticals, INC | $28.23 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.84 | 2025 | Gvoke Hypopen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $21.17 | 2024 | Aquabeam System |
| Becton, Dickinson and Company | $20.84 | 2024 | Bd Onclarity |
| Aimmune Therapeutics, INC. | $19.50 | 2025 | Zenpep |
| Boston Scientific Corporation | $19.43 | 2025 | Watchman Access System |
| Corcept Therapeutics | $18.89 | 2025 | Korlym |
| Dynavax Technologies Corporation | $17.96 | 2025 | Heplisav-B |
| Sumitomo Pharma America, INC. | $17.00 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $15.34 | 2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $13.82 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Valdman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.